Regorafenib is intended to treat patients with metastatic colorectal cancer whose disease has progressed after standard therapy.
FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. FDA completes a priority review within six months of receiving the new drug application rather than the standard 10-month review cycle.
The application for regorafenib was filed at the end of April.
Related Articles on Colon Cancer:
Study: CT Colonography Effective Screening Tool for Colon Cancer
Univ. of FL Researchers Receive $1.5M to Study Colon Cancer
‘Pill Colonoscopy’ Under Development in Boston
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
